Zogenix Inc ZGNX:NASDAQ

Last Price$40.06Cboe Real-Time Last Sale as of 9:55AM ET 6/24/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.56(1.38%)
Bid (Size)$40.00 (200)
Ask (Size)$40.18 (200)
Day Low / High$40.35 - 40.77
Volume4.4 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 06/24/2019

 

Zogenix Inc ( NASDAQ )

Price: $40.06
Change: -0.56 (1.38%)
Volume: 4.4 K
9:55AM ET 6/24/2019
 
 

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $10.77
Change: -0.18 (1.64%)
Volume: 31.8 K
9:58AM ET 6/24/2019
 
 

Pacira Biosciences Inc ( NASDAQ )

Price: $43.46
Change: -0.52 (1.18%)
Volume: 37.7 K
9:56AM ET 6/24/2019
 
 

Madrigal Pharmaceuticals Inc ( NASDAQ )

Price: $103.49
Change: -1.37 (1.31%)
Volume: 3.4 K
9:45AM ET 6/24/2019
 
 

Supernus Pharmaceuticals Inc ( NASDAQ )

Price: $30.55
Change: -0.30 (0.97%)
Volume: 8.5 K
9:58AM ET 6/24/2019
 

Read more news Recent News

Zogenix Narrows Q1 Net Loss, R&D Expenses Rise
5:31PM ET 5/08/2019 MT Newswires

Zogenix (ZGNX) reported a Q1 net loss of $0.83 a share, narrowed from the year-earlier loss of $0.87 a share and better than the consensus on Capital IQ...

After Hours Watch List Scorecard: PHAS, CCNI, ZGNX
5:16PM ET 4/09/2019 MT Newswires

Here's how the stocks on Monday's After Hours Watch List performed during today's regular session AFTER HOURS REGULAR SESSION PHAS ...

Analyst Actions: Mizuho Securities Cuts Zogenix's Price Target to $58 From $71, Reiterates Buy Rating
12:04PM ET 4/09/2019 MT Newswires

Zogenix's (ZGNX) average rating among analysts is a buy. Price: 40.06, Change: -11.79, Percent Change: -22.74 ...

Analyst Actions: Guggenheim Downgrades Zogenix to Neutral From Buy
9:31AM ET 4/09/2019 MT Newswires

Zogenix's (ZGNX) average rating among analysts is a buy, with an average price target of $70. Price: 38.15, Change: -13.70, Percent Change: -26.42 ...

Company Profile

Business DescriptionZogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. View company web site for more details
Address5959 Horton Street
Emeryville, California 94608
Phone+1.510.550.8300
Number of Employees90
Recent SEC Filing05/28/20194
President, Chief Executive Officer & DirectorStephen James Farr
CFO, Secretary, Treasurer & Executive VPMichael Patrick Smith
Chief Medical Officer & Executive Vice PresidentBradley S. Galer
Vice President, Legal Council & Compliance OfficeSteven A. Johnson

Company Highlights

Price Open$40.61
Previous Close$40.62
52 Week Range$33.43 - 62.75
Market Capitalization$1.7 B
Shares Outstanding42.4 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement08/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.19
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-28.01%

Analyst Ratings as of 06/14/2019

Buy
9
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset